5-氨基-8-甲氧基异喹啉 | 321921-99-7

• 物质功能分类: 医药中间体 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 5-氨基-8-甲氧基异喹啉
• 英文名称: 8-methoxy-isoquin-5-ylamine
• 英文别名: 8-Methoxyisoquinolin-5-amine
• CAS: 321921-99-7
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: JGYFOOINAVAFBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-chloro-3-trifluoromethylbenzylisocyanate 、 5-氨基-8-甲氧基异喹啉 以 乙腈 为溶剂， 反应 0.08h， 生成 1-(4-chloro-3-trifluoromethyl-benzyl)-3-(8-methoxy-isoquinolin-5-yl)-urea
  参考文献：
  名称：

  [EN] NAPHTHOL, QUINOLINE AND ISOQUINOLINE-DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR
  [FR] MODULATEURS UREIQUES DU RECEPTEUR VANILLOIDE VR1 DERIVES DU NAPHTOL, DE LA QUINOLINE ET DE L'ISOQUINOLINE

  摘要：

  公开号：

  WO2004007459A3
• 作为产物：
  描述：

  8-甲氧基-5-亚硝基异喹啉 在 镍 肼 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 5-氨基-8-甲氧基异喹啉
  参考文献：
  名称：

  由N-烷基-5-氨基异喹啉鎓盐合成吲哚-4-羧醛和4-乙酰吲哚

  摘要：

  在含有过量的2：1亚硫酸氢钠-亚硫酸钠的两相乙酸烷基酯-水体系中加热时，将N-烷基-5-氨基异喹啉鎓盐（8a-d）转化为吲哚-4-羧醛（1a-c）混合物。由4-甲基-2-氰基甲基异喹啉鎓溴化物8f以相同的方式制备4-乙酰基吲哚1e。

  DOI：

  10.1002/jhet.5570370545

文献信息

• Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain
  申请人：Brown Elizabeth Rebecca

  公开号：US20050107388A1

  公开（公告）日：2005-05-19

  The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilising them.

  本发明提供了式（I）的化合物；其药学上可接受的盐和N-氧化物，其中A，B，D和E是C或N，但其中一个或多个是N，R1，R2，R3，R4，R5和R6是简单的取代基，n是0-3，y是芳基，杂环芳基，碳环芳基或融合的碳环芳基基团；作为VR-1拮抗剂，用于治疗疼痛和/或炎症占优势的疾病或症状；同样的用于制造药物、包含它们的制剂和利用它们的治疗方法。
• Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain
  申请人：——

  公开号：US07285563B2

  公开（公告）日：2007-10-23

  The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R1, R2, R3, R4, R5 and R6 are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilizing them

  本发明提供了式(I)的化合物；其药学上可接受的盐和N-氧化物，其中A、B、D和E是C或N，但至少一个是N，R1、R2、R3、R4、R5和R6是简单的取代基，n为0-3，y是芳香基，杂环芳基，碳环基或融合碳环基；作为VR-1拮抗剂，用于治疗疼痛和/或炎症占优势的疾病或症状；将其用于制造药物，制备包含它们的制药组合物和利用它们的治疗方法。
• NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS
  申请人：Biodol Therapeutics

  公开号：EP4353712A1

  公开（公告）日：2024-04-17

  The present invention relates to a compound of formula (I) or any of its acceptable salts (I) wherein W, X, Y and Z each independently represents =CH- or -N-, provided that at most two of W, X, Y and Z both represent a -N- group, R1 represents a linear or cyclic nitrogen containing (C4-C8)alkyl group, said group being a non aromatic (C4-C8)alkyl group that can be linear or cyclic comprising 4 to 8 carbon atoms that contains at least one nitrogen atom, that interrupts said alkyl chain, said group being optionally interrupted by one or two oxygen atoms and optionally substituted by a (C1-C4)alkyl group or by a (C3-C6)cycloalkyl group, R2 represents a hydrogen atom, a halogen atom, a (C1-C4)alkyl group, a (C1-C4)alkoxy group, a (C1-C4)fluoroalkyl group, a -CO-(C1-C4)alkyl group, a -CONH2 group, a SO2-NH2 group or a cyano group, R3 represents a hydrogen atom, a halogen atom, a (C1-C4)alkyl group, a (C1-C4)alkoxy group, a (C1-C4)fluoroalkyl group, a cyano group, a (C1-C4)alkylsulfonyl group or a SO2-NH2 group, and R4, R5 and R6 independently represent a hydrogen atom, a halogen atom, a -COOH group, a (C1-C4)fluoroalkyl group, a (C1-C4)alkylsulfonyl group or a (C1-C4)alkoxy group. The present invention further related to a pharmaceutical composition comprising it and to its use in the prevention and/or the treatment of pain.

  本发明涉及式(I)的化合物或其任何可接受的盐， 其中W、X、Y和Z各自独立地表示=CH-或-N-，并且至多两个的W、X、Y和Z同时表示-N-基团，R1表示线性或环状含氮(C4-C8)烷基，所述基团是非芳族的C4-C8烷基，所述基团包含4至8个碳原子，其中至少包含一个打断所述烷基链的氮原子，所述基团可被一个或两个氧原子打断，并且可被(C1-C4)烷基或(C3-C6)环烷基取代；R2表示氢原子、卤素原子、C1-C4烷基、C1-C4烷氧基、C1-C4氟代烷基、-CO-(C1-C4)烷基、-CONH2基团、SO2-NH2基团或氰基团，R3表示氢原子、卤素原子、C1-C4烷基、C1-C4烷氧基、C1-C4氟代烷基、氰基团、C1-C4烷基磺酰基或SO2-NH2基团，R4、R5和R6各自独立地表示氢原子、卤素原子、-COOH基团、C1-C4氟代烷基、C1-C4烷基磺酰基或C1-C4烷氧基。本发明进一步涉及包含它的药物组合物，及其在预防和/或治疗疼痛中的用途。
• US7183411B2
  申请人：——

  公开号：US7183411B2

  公开（公告）日：2007-02-27
• US7285563B2
  申请人：——

  公开号：US7285563B2

  公开（公告）日：2007-10-23